1. Scrip
  2. >>Business

Contrave Rxs Jump In Q1, But TV Commercial Runs Afoul Of FDA

 
• By Brenda Sandburg

Orexigen touts 39% growth in US sales of its obesity drug; agency objects to advertisement for excluding risk information.

Weight-loss-pills-tape-measure_3113223_1200x675

Orexigen Therapeutics Inc. was upbeat earlier this month when it told investors about the growth in prescriptions and market share of its weight-loss drug Contrave (naltrexone/bupropion). But the good news was soon followed by a letter from the US FDA objecting to the product's television ad.

The agency told the company in a May 18

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.